STOCK TITAN

Tempus AI extends AstraZeneca deal with $200M commitment

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Tempus AI, Inc. and AstraZeneca AB amended their Master Services Agreement, establishing a new five-year financial commitment period effective January 1, 2027, and extending the agreement through December 31, 2031. AstraZeneca committed to $200 million in fees to be paid or payable to Tempus under the MSA and other agreements between the parties and their affiliates during the renewal term. The commitment represents an annual target spend of $40 million across Tempus’s existing and future products and services, with a minimum of $32 million in fees in each calendar year.

If the $200 million aggregate commitment is not met by the end of the renewal term, the agreement extends through December 31, 2032 to address the shortfall. AstraZeneca may terminate the MSA for convenience at any time; if its financial commitments remain unfulfilled as of the effective date of termination, AstraZeneca is liable to pay Tempus the shortfall against the $200 million commitment.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Aggregate fee commitment $200 million Fees to be paid or payable during the renewal term under the MSA and other agreements between the parties and their affiliates.
Annual target spend $40 million Across Tempus’s existing and future products and services during the renewal term.
Annual minimum fees $32 million Minimum fees in each calendar year of the renewal term.
Financial commitment period Five years Effective January 1, 2027; the agreement term runs through December 31, 2031.
Agreement term end December 31, 2031 End of the renewal term, subject to further extension under certain conditions.
Conditional extension end December 31, 2032 If the $200 million aggregate commitment is not met by the end of the renewal term.
Master Services Agreement technical
"amended their Master Services Agreement"
A master services agreement is a standing contract that sets the main terms, responsibilities, pricing framework and processes for future work between two parties, allowing individual projects or orders to be added later without renegotiating core terms. For investors, it signals predictability and reduced legal friction around revenue streams and costs—like a subscription plan for services that makes future income and obligations easier to forecast and value.
Renewal Term regulatory
"extends the term of the MSA through December 31, 2031"
termination for convenience regulatory
"right to terminate the MSA for convenience at any time"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AstraZeneca commit to pay Tempus AI (TEM) under the amended agreement?

AstraZeneca committed to $200 million in fees to be paid or payable to Tempus under the MSA and other agreements between the parties and their affiliates during the renewal term. The commitment targets $40 million in annual spend across Tempus’s existing and future products and services.

What is AstraZeneca’s minimum annual commitment to Tempus AI (TEM)?

AstraZeneca agreed to a minimum of $32 million in fees in each calendar year of the renewal term. The annual target spend is $40 million across Tempus’s existing and future products and services.

What happens if AstraZeneca does not meet its commitment to Tempus AI (TEM)?

If the $200 million aggregate commitment is not met by the end of the renewal term, the term extends by one year through December 31, 2032, to address the shortfall.

Can AstraZeneca terminate its agreement with Tempus AI (TEM)?

AstraZeneca may terminate the MSA for convenience at any time. If its financial commitments are unfulfilled as of the effective date of termination, AstraZeneca is liable to pay Tempus the shortfall against its $200 million commitment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001717115 0001717115 2026-11-16 2026-11-16
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

Tempus AI, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Nevada   001-42130   47-4903308
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

600 West Chicago Avenue, Suite 510  
Chicago, Illinois   60654
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (800) 976-5448

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Class A common stock, $0.0001 par value per share   TEM   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01

Entry into a Material Definitive Agreement.

On November 16, 2026, Tempus AI, Inc. (the “Company”) and AstraZeneca AB (“AstraZeneca”) entered into a Fifth Amendment (the “Amendment”) to the Master Services Agreement, dated November 17, 2021, between the Company and AstraZeneca (as previously amended, the “MSA”). The Amendment, which is effective as of January 1, 2027, establishes a new five-year financial commitment period between AstraZeneca and the Company, extends the associated strategic collaborator benefits provided to AstraZeneca under the existing MSA, and extends the term of the MSA through December 31, 2031 (the “Renewal Term”), subject to further extension under certain conditions.

Pursuant to the Amendment, AstraZeneca has committed to an aggregate of $200 million in fees to be paid or payable to the Company under the MSA and other agreements between the parties and their affiliates during the Renewal Term, representing an annual target spend of $40 million across the Company’s existing and future products and services. AstraZeneca has also agreed to a minimum of $32 million in such fees in each calendar year of the Renewal Term. If the $200 million aggregate commitment has not been met by the end of the Renewal Term, the Renewal Term will be extended by one year, through December 31, 2032, to address the shortfall.

AstraZeneca continues to have the right to terminate the MSA for convenience at any time. The Amendment provides that, if AstraZeneca has not fulfilled its financial commitments as of the effective date of any such termination, AstraZeneca will be liable to pay the Company for any shortfall of its $200 million financial commitment.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.

  

Description

10.1^    Fifth Amendment to Master Services Agreement by and between Registrant and AstraZeneca AB, dated November 16, 2026.
104*    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

^

Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and are the type that the registrant treats as private or confidential.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Tempus AI, Inc.
Dated: November 18, 2026     By:  

/s/ James Rogers

      James Rogers
      Chief Financial Officer

Filing Exhibits & Attachments

4 documents

Keep reading